NRXP | in search for the next MRNA

After a perfect touch of the .618 Fib retracement level, now NRXP is ready to aim higher!
Get ready for action!
My first price target is 35usd.

Today NRx was granted Fast Track Designation by the U.S. Food and Drug Administration for ZYESAMI (aviptadil) for the treatment of Critical COVID-19 with respiratory failure!

NRx Pharmaceuticals has also a Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife COVID Vaccine.

NRx Pharmaceuticals has Successful Commercial Formulation for ZYESAMI (aviptadil) and Stockpiling of COVID-19 Medication Subject to Regulatory Approval.
ZYESAMI Helps Prevent "Cytokine Storm" in Patients with COVID-19